1. Executive Summary

2. Worldwide – Epilepsy Drugs Market Analysis (2013 – 2021)

3. Worldwide – Epilepsy Drugs Market Share (2013 – 2021)

4. Key Drivers and Inhibitors of the Epilepsy Drugs Market
4.1 Market Drivers
4.2 Inhibitors

5. Worldwide – Epilepsy Drugs Brand Market Performance (2013 – 2021)
5.1 Vimpat(Lacosamide) – UCB
5.2 Keppra(Levetiracetam) – UCB
5.3 Briviact(Brivaracetam) – UCB
5.4 Lamictal(Lamotrigine) – GlaxoSmithKline
5.5 Neurontin (Gabapentin) – Pfizer
5.6 Depakine (Sodium Valproate) – Sanofi
5.7 Sabril (Vigabatrin) – Lundbeck
5.8 Onfi(Clobazam) – Lundbeck
5.9 Fycompa(Perampanel) – EISAI
5.10 Inovelon/Banzel(Rufinamide) – EISAI
5.11 Zonegran (Zonisamide) – EISAI
5.12 Zebinix (Eslicarbazepine Acetate) – EISAI

6. Epilepsy Drugs Market – Major Deal Types
6.1 Epilepsy Drugs Market – Collaboration Deals
6.2 Epilepsy Drugs Market – Licensing Agreement
6.3 Epilepsy Drugs Market – Partnerships Deals

7. Key Companies Analysis
7.1 UCB
7.1.1 Business Overview
7.1.2 Epilepsy Drugs – Latest Development & Trends
7.1 EISAI
7.1.1 Business Overview
7.1.2 Epilepsy Drugs – Latest Development & Trends
7.2 Pfizer
7.2.1 Business Overview
7.2.2 Epilepsy Drugs – Latest Development & Trends
7.3 Sanofi
7.3.1 Business Overview
7.3.2 Epilepsy Drugs – Latest Development & Trends
7.4 Lundbeck
7.4.1 Business Overview
7.4.2 Epilepsy Drugs – Latest Development & Trends

List of Figures

Figure 2–1: Worldwide – Epilepsy Drugs Market (Million US$),2013 – 2016
Figure 2–2: Worldwide – Forecast for Epilepsy Drugs Market (Million US$),2017 – 2021

Figure 5–1: Worldwide – Vimpat Drug Sales (Million US$), 2013 – 2016
Figure 5–2: Worldwide – Forecast for Vimpat Drug Sales (Million US$), 2017 – 2021
Figure 5–3: Worldwide – Keppra Drug Sales (Million US$), 2013 – 2016
Figure 5–4: Worldwide – Forecast for Keppra Drug Sales (Million US$), 2017 – 2021
Figure 5–5: Worldwide – Briviact Drug Sales (Million US$), 2016 – 2021
Figure 5–6: Worldwide – Lamictal Drug Sales (Million US$), 2013 – 2016
Figure 5–7: Worldwide – Forecast for Lamictal Drug Sales (Million US$), 2017 – 2021
Figure 5–8: Worldwide – Neurotin Drug Sales (Million US$), 2013 – 2016
Figure 5–9: Worldwide – Forecast for Neurotin Drug Sales (Million US$), 2017 – 2021
Figure 5–10: Worldwide – Depakine Drug Sales (Million US$), 2013 – 2016
Figure 5–11: Worldwide – Forecast for Depakine Drug Sales (Million US$), 2017 – 2021
Figure 5–12: Worldwide – Sabril Drug Sales (Million US$), 2013 – 2016
Figure 5–13: Worldwide – Forecast for Sabril Drug Sales (Million US$), 2017 – 2021
Figure 5–14: Worldwide – Onfi Drug Sales (Million US$), 2013 – 2016
Figure 5–15: Worldwide – Forecast for Onfi Drug Sales (Million US$), 2017 – 2021
Figure 5–16: Worldwide – Fycompa Drug Sales (Million US$), 2013 – 2016
Figure 5–17: Worldwide – Forecast for Fycompa Drug Sales (Million US$), 2017 – 2021
Figure 5–18: Worldwide – Inovelon/Banzel Drug Sales (Million US$), 2013 – 2016
Figure 5–19: Worldwide – Forecast for Inovelon/Banzel Drug Sales (Million US$), 2017 – 2021
Figure 5–20: Worldwide – Zonegran Drug Sales (Million US$), 2013 – 2016
Figure 5–21: Worldwide – Forecast for Zonegran Drug Sales (Million US$), 2017 – 2021
Figure 5–22: Worldwide – Zebinix Drug Sales (Million US$), 2013 – 2016
Figure 5–23: Worldwide – Forecast for Zebinix Drug Sales (Million US$), 2017 – 2021
 
List of Tables

Table 3 1: Worldwide – Epilepsy Drugs Market Share(Percent),2013 – 2016
Table 3 2: Worldwide – Forecast for Epilepsy Drugs Market Share(Percent),2017 – 2021

Table 4 1: Epilepsy Branded Drugs Price List(US$),2017

Table 6 1: Collaboration Deals in Epilepsy Drug Market, 2008 – 2017
Table 6 2: Licensing Agreement in Epilepsy Drug Market, 2008 – 2016
Table 6 3: Partnerships Deals in Epilepsy Drug Market, 2008 – 2016